Apeloa Pharmaceutical reports sharp Q3 revenue, profit declines

Apeloa Pharmaceutical reported a decrease in its Q3 2025 performance, with operating revenue falling by 18.94% to 2,319,396,045.96 yuan compared to the same period last year. Net profit attributable to shareholders saw an even steeper decline of 43.95%, reaching 137,218,813.55 yuan. Basic earnings per share also decreased by 43.19% to 0.1202 yuan.

For the first nine months of 2025, operating revenue decreased by 16.43% to 7,763,882,133.27 yuan, and net profit attributable to shareholders declined by 19.48% to 700,266,086.74 yuan. Investment income, however, surged by 515.80% to 33,819,960.74 yuan, primarily due to gains from the disposal of subsidiaries.

Total assets stood at 12,101,962,799.34 yuan at the end of the reporting period, a 4.93% decrease from the previous year-end. Net cash flow from operating activities decreased by 33.60% to 774,024,106.67 yuan, mainly due to lower operating revenue and tax refunds.